Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13792972 | 0.88 | KDM4E (0.53) | KDM4EDNM1PAOXALDH1A1MEN1 | |
| SCHEMBL8433587 | 0.79 | DNM1 (0.44) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL22068306 | 0.79 | LMNA (0.31) | KDM4ELMNA | |
| SCHEMBL29460411 | 0.79 | MCL1 (0.39) | ALDH1A1CA1CA2MCL1LMNA | |
| SCHEMBL8253762 | 0.78 | ALDH1A1 (0.38) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL22752133 | 0.77 | CYP2C9 (0.31) | CYP2C9CYP2C19KDM4EANPEP | |
| SCHEMBL2507441 | 0.77 | CYP2C9 (0.44) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL27293107 | 0.77 | PAOX (0.47) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL9189697 | 0.77 | — | — | |
| SCHEMBL14542570 | 0.76 | KDM4E (0.45) | CYP2C19KDM4EALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1529053-B1 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY | ZAMBON SPA (IT) | 2011-05-18 | — | — | EP | claimed |
| EP-2258708-A1 | Macrolide compounds endowed with antiinflammatory activity | Zambon S.p.A. (IT) | 2010-12-08 | — | — | EP | claimed |
| US-7488811-B2 | Macrolide compounds endowed with antiinflammatory activity | ZAMBON GROUP S.P.A. (IT) | 2009-02-10 | — | — | US | claimed |
| US-20060058246-A1 | Macrolide compounds endowed with antiinflammatory activity | ZAMBON GROUP S.P.A. (IT) | 2006-03-16 | — | — | US | claimed |
| EP-1529053-A2 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY | ZAMBON GROUP S.p.A. (IT) | 2005-05-11 | — | — | EP | claimed |
| WO-2004013153-A2 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2004-02-12 | — | — | WO | claimed |
| EP-2258708-A1 | Macrolide compounds endowed with antiinflammatory activity | Zambon S.p.A. (IT) | 2010-12-08 | — | — | EP | disclosed |
| US-7704960-B2 | Macrolide compounds endowed with antiinflammatory activity | ZAMBON GROUP S.P.A. (IT) | 2010-04-27 | — | — | US | disclosed |
| US-7544703-B2 | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544703-B2 | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20090054357-A1 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2009-02-26 | — | — | US | disclosed |
| US-7488811-B2 | Macrolide compounds endowed with antiinflammatory activity | ZAMBON GROUP S.P.A. (IT) | 2009-02-10 | — | — | US | disclosed |
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20060058246-A1 | Macrolide compounds endowed with antiinflammatory activity | ZAMBON GROUP S.P.A. (IT) | 2006-03-16 | — | — | US | disclosed |
| EP-1529053-A2 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY | ZAMBON GROUP S.p.A. (IT) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004013153-A2 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054357-A1 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY | CEL, MPO, IL6 | PRMT3 3023/4885CARM1 3673/4885PRMT6 3993/4885 |
| US-20060058246-A1 | Macrolide compounds endowed with antiinflammatory activity | CEL, MPO, IL6 | PRMT3 3023/4885CARM1 3673/4885PRMT6 3993/4885 |
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | FLT4, FLT1, TIE1 | PRMT3 916/4885CARM1 744/4885PRMT6 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.